Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases 10,000 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was bought at an average price of C$1.95 per share, with a total value of C$19,500.00.

Cardiol Therapeutics Price Performance

Shares of CRDL stock opened at C$1.95 on Wednesday. The firm has a fifty day moving average of C$2.41 and a two-hundred day moving average of C$2.73. The firm has a market cap of C$136.27 million, a P/E ratio of -4.43 and a beta of 0.70. Cardiol Therapeutics Inc. has a 1-year low of C$1.07 and a 1-year high of C$4.26. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.